Caixin1 day agoAnalysis: More Chinese Cities Drop Regular Covid Testing as Cost Concerns MountCaixin Global - By Zhang YukunCities across China have begun rolling back regular testing for Covid-19 — a costly scheme that some experts say may not be necessary — dropping the …
Caixin4 days agoAnalysis: What’s Next for China’s Generic Drug Industry?Caixin Global - By Gao Yi(Blue View) — Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. Ltd. won U.S. regulatory approval in May to market its iodixanol injection for …
Caixin6 days agoAnalysis: Bilibili’s Loss Widens as Costs SpiralCaixin Global - By Li Tao and Mou YafeiNasdaq-listed Bilibili Inc. saw a widening loss in the first quarter this year, as the Chinese video-streaming and mobile gaming giant spent big to …
CaixinAnalysis: New Oriental’s Livestreaming a Hit, but Hurdles Remain to Long-Term SuccessCaixin Global - By Zizan WangChinese tutoring giant New Oriental’s pivot to livestreaming e-commerce took off in the first half of June thanks to auspicious social media …
CaixinAnalysis: In China’s Medical Beauty Business, Only the Fittest Now SurviveCaixin Global - By Li Leyan, Zhang Jiawen and Nie YinghaoIntensified regulation has left China’s once-hot medical beauty industry primed for a shake-up that looks likely to favor companies whose core …
CaixinAnalysis: China’s Covid Test Firms Wave Goodbye to the Days of Easy MoneyCaixin Global - By Zhao Tiantian, Mei Ziyi and Li TaoChinese Covid-19 test companies are facing shrinking profits despite higher demand, as the government has further cut prices and competition has …
